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Abstract: Aquaporins (AQPs) are water channel proteins that are essential to life, being expressed in
all kingdoms. In humans, there are 13 AQPs, at least one of which is found in every organ system.
The structural biology of the AQP family is well-established and many functions for AQPs have
been reported in health and disease. AQP expression is linked to numerous pathologies including
tumor metastasis, fluid dysregulation, and traumatic injury. The targeted modulation of AQPs
therefore presents an opportunity to develop novel treatments for diverse conditions. Various
techniques such as video microscopy, light scattering and fluorescence quenching have been used to
test putative AQP inhibitors in both AQP-expressing mammalian cells and heterologous expression
systems. The inherent variability within these methods has caused discrepancy and many molecules
that are inhibitory in one experimental system (such as tetraethylammonium, acetazolamide, and
anti-epileptic drugs) have no activity in others. Some heavy metal ions (that would not be suitable for
therapeutic use) and the compound, TGN-020, have been shown to inhibit some AQPs. Clinical trials
for neuromyelitis optica treatments using anti-AQP4 IgG are in progress. However, these antibodies
have no effect on water transport. More research to standardize high-throughput assays is required
to identify AQP modulators for which there is an urgent and unmet clinical need.
Keywords: aquaporin; AQP inhibitors; AQP modulators; functional assays; AQP expression; AQPs
in disease; AQP structure; TGN-020; heavy metals; small molecule inhibitors
1. Aquaporin Structure
Aquaporins (AQPs) are transmembrane proteins that facilitate the bidirectional transport of water
across cell membranes; water flows through AQP pores following an osmotic gradient to support
water homeostasis [1–3]. A subset of the AQP family, the aquaglyceroporins, also allows the transport
of glycerol and other small neutral solutes such as urea and ammonia [4–7]. These include AQP3,
AQP7, AQP9, and AQP10. Currently, there are 13 known mammalian AQPs, each with a structure
comprising six membrane-spanning helices (Table 1). The amino- and carboxy-termini of APQs are
both intracellular [3,8]. Two opposing, shorter helices do not span the entire membrane (Figure 1),
but form the pore itself [3,9,10]. These half helices contain the family’s signature triplet amino acid
NPA (Asn-Pro-Ala) motif, as seen in Figure 1a [8,11]. The residues in this motif orient water molecules
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to prevent protons from entering the channel, as well as acting as the hydrogen bond donors and
acceptors that facilitate the passage of water molecules [3]. The narrowest segment of the AQP channel
is within the transmembrane region of the pore. For AQP1, it is 2.8 Å in diameter, which is similar to
the size of a single water molecule. This feature means water molecules pass through AQPs in single
file. A high resolution (0.88Å) X-ray crystal structure of a yeast AQP, Aqy1, revealed that the selectivity
filter within the pore contains four positions for water molecules and that it is not possible for these
positions to be occupied simultaneously. Instead they travel in a pairwise fashion, filling two of these
positions at a time [12].
AQPs form homotetramers within the plasma membrane. Each homotetramer consists of four
water channels (Figure 1b) [13,14]. Each water channel is functionally independent. It has been shown
that channel pore size can sometimes be variable. When the residues responsible for the widening and
narrowing of the channel entrance were in an ‘open’ state, molecular dynamics simulations suggested
that the channel entrance was wider in monomeric than tetrameric AQP5, although it is not clear how
this might affect water permeability [15]. For AQP4, functional and mutagenesis studies suggested that
non-tetrameric AQPs have the same water permeability as those found in tetramers [16]. Although the
reason AQPs form tetramers is not fully understood [17,18], it has been shown that non-tetrameric
forms of AQP4 do not undergo hypotonicity-induced intracellular trafficking [16].
A controversial topic in AQP biology, related to their homotetrameric nature, has been their
conduction of ions and whether this takes place. AQP tetramers contain a potential fifth central
pore as shown in Figure 1b, reminiscent of cation channels such as Kir 2.1 [19]. The use of forskolin
has been reported to induce cationic permeability in AQP1 [20], however, follow-up experiments by
different groups failed to replicate this [21]. Direct binding of cGMP to AQP1 expressed in Xenopus
oocytes has been shown to cause an ionic current after cGMP binding to a predicted site found in
the AQP1 carboxyl tail [22]. The central pore of AQP1 was also found to be gas permeable using
molecular dynamics simulations. However, conduction of O2 and CO2 through AQP1 may only be
physiologically relevant in membranes of low gas permeability where there are high concentrations of
AQPs [23]. Recently, a review of evidence for the gas permeability of AQPs suggested that that it may
be functionally important in some cells, but not in others [24]. Less controversially, AQP6 is permeable
to nitrate and chloride ions [25–28], and AQP8 is permeable to ammonia [29–31]. In a high resolution
X-ray crystal structure of human AQP5, however, a lipid molecule co-crystallized with the protein,
occluding the fifth central pore, suggesting another possible role [32].
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Figure 1. Aquaporin structure: (a) primary sequence of Aquaporin 4 (AQP4), the water channel with 
the highest recorded water permeability (see Table 1), highlighting the NPA (Asn-Pro-Ala) residues 
in yellow; (b) tertiary structure of the AQP4 homotetramer showing four water pores (marked with a 
blue dot) and the ‘fifth pore’ produced by formation of the tetramer (marked with a red dot). Adapted 
from an image originally published in [33].  
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Table 1. A summary of AQPs 0–12 showing the information available on their structure, permeability,
location within the body and pathophysiology. The osmotic water permeability coefficient (Pf) relates
the magnitude of bulk water flow across a membrane in response to hydrostatic or osmotic pressure
gradients to the magnitude of the driving pressure gradient. It depends on both the permeability
of individual water channels and the density of channels in the membrane. Pgly is the glycerol
permeability coefficient. The single channel osmotic water permeability coefficient (pf) is also given
where available.
AQP Structural
Information
Available
Water Permeability
(Glycerol Permeability Is
Also Given for
Aquaglyceroporins)
Main Locations in
Humans
Disease States References
AQP0 PDB ref: 1YMG
Resolution: 2.2 Å
Species: Bos taurus
Method: X-ray
diffraction
Amino acids: 263
Xenopus oocytes—
5 ng cRNA
Pf: 1.3 × 10−3 cm/s
(control with no AQP
0.67 × 10−3 cm/s)
pf: 0.25 × 10−14 cm3/s
—single channel
permeability
Lens Mutations in the
gene for AQP0
often result in
bilateral cataracts
[7,34–36]
AQP1 PDB ref: 1FQY
Resolution: 3.8 Å
Species: Homo sapiens
Method: Electron
crystallography
Amino acids: 269
Xenopus oocytes—
5 ng cRNA
Pf: 19 × 10−3 cm/s (control
0.67 × 10−3 cm/s)
pf: 6.0 × 10−14 cm3/s
—single channel
permeability
Erythrocytes
Choroid plexus
Eye epithelium
Corneal epithelium
Bile duct
Capillaries
Nephron
Airways
Skeletal muscle
Deficiency causes
inability to
concentrate urine
Tumors with AQP1
have increased
metastases and
invasiveness
Altered pain
sensation
[3,7,37–40]
AQP2 PDB ref: 4NEF
Resolution: 2.75 Å
Species: Homo sapiens
Method: X-ray
diffraction
Amino acids: 242
Xenopus oocytes—
5 ng cRNA
Pf: 10 × 10−3 cm/s (control
0.67 × 10−3 cm/s)
pf: 3.3 × 10−14 cm3/s
—single channel
permeability
Collecting duct
cells
Deficiency causes
diabetes insipidus
[7,39,41,42]
AQP3 No structural data
available
UniProtKB—O92482
Species: Homo sapiens
Amino acids: 292
Xenopus oocytes—
5 ng cRNA
Pf: 8.0 × 10−3 cm/s
(control 0.67 × 10c3 cm/s)
pf: 2.1 × 10−14 cm3/s
—single channel
permeability
Pgly: 23 × 10−6 cm/s
Epidermis
Collecting duct
cells
Erythrocytes
Skin dehydration
Psoriasis
Tumor
invasiveness and
metastases
[7,43–45]
AQP4 PDB ref: 3GD8
Resolution: 1.8 Å
Species: Homo sapiens
Method: X-ray
diffraction
Amino acids: 223
Xenopus oocytes—
5 ng cRNA
Pf: 29 × 10−3 cm/s (control
0.67 × 10−3 cm/s)
pf: 24 × 10−14 cm3/s
—single channel
permeability
Astrocytes
Parietal cells
Collecting duct
cells
Retina
Cytotoxic edema
Vasogenic edema
Neuromyelitis
optica
[7,44,46]
AQP5 PDB ref: 3D9S
Resolution: 2 Å
Species: Homo sapiens
Method: X-ray
diffraction
Amino acids: 266
Xenopus oocytes—
5 ng cRNA
Pf: 10 × 10−3 cm/s (control
0.67 × 10−3 cm/s)
pf: 5.0 × 10−14 cm3/s
—single channel
permeability
Salivary, lacrimal
and sweat glands
Lung
Sjögren’s
syndrome
[7,32,47]
AQP6 No structural data
available
UniProtKB—Q13520
Species: Homo sapiens
Amino acids: 282
Xenopus oocytes—
5–10 ng cRNA
Pf: 1.2 × 10−3 cm/s
(control 0.53 × 10−3 cm/s)
(93 × 10 −4 cm/s after
activation with mercury)
No single channel data
available.
Collecting duct Unknown [48,49]
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Table 1. Cont.
AQP Structural
Information
Available
Water Permeability
(Glycerol Permeability Is
Also Given for
Aquaglyceroporins)
Main Locations in
Humans
Disease States References
AQP7 No structural data
available
UniProtKB—O14520
Species: Homo sapiens
Amino acids: 342
Xenopus oocytes—
5 ng cRNA
Pf: 18.6 × 10−3 cm/s
(control 1.7 × 10−3 cm/s)
Pgly: 18.9 × 10−6 cm/s
No single channel data
available
Adipocytes
Testis
Proximal kidney
tubule
Adipocyte
hypertrophy
[4,8]
AQP8 No structural data
available
UniProtKB—O94778
Species: Homo sapiens
Amino acids: 261
Xenopus oocytes—
10 ng cRNA
Pf: 22 × 10−3 cm/s (control
0.8 × 10−3 cm/s)
pf: 8.2 × 10−14 cm3/s
—single channel
permeability
Pancreas
Testis
Unknown [44,50]
AQP9 No structural data
available
UniProtKB—O43315
Species: Homo sapiens
Amino acids: 295
Xenopus oocytes—
10 ng cRNA
Pf: 12.3 × 10−3 cm/s
(control 1.8 × 10−3 cm/s)
Pgly: ~10 × 10−6 cm/s
(controls: H2O 0 cm/s,
AQP4 ~2.5 × 10−6 cm/s)
No single channel data
available
Hepatocytes
Osteoclasts
Astrocytes
Leukocytes
Osteoporosis [43,51]
AQP10 PDB ref: 6F7H
Resolution: 2.3 Å
Species: Homo sapiens
Method: X-ray
diffraction
Amino acids: 301
Xenopus oocytes—
10 ng cRNA
Pf: ~0.05 × 10−3 cm/s
(controls: negative control
~0.02 × 10−3 cm/s, AQP8
~0.2 × 10−3 cm/s
No single channel data
available
Intestinal epithelial
cells
Adipocytes
Unknown [44,52]
AQP11 No structural data
available
UniProtKB—Q8NBQ7
Species: Homo sapiens
Amino acids: 271
Spodoptera frugiperda—Sf9
membrane vesicles
containing 1 µg mouse
AQP11 protein
Pf: 29.8 × 10−3 cm/s
(controls: negative control
8.2 × 10−3 cm/s,
246.1 × 10−3 cm/s human
AQP1, 197.7 × 10−3 cm/s
His-rat AQP4)
No single channel data
available
Testis
Thymus
Kidney
Liver
Polycystic kidneys [44,53]
AQP12 No structural data
available
AQP12A
UniProtKB—Q8IXF9
AQP12B
UniProtKB—A6NM10
Species: Homo sapiens
Amino acids: 295
Pancreatic rough
endoplasmic reticulum
vesicles—600 µg total RNA
Pf: 13.0 × 10−3 cm/s
(control 15.1 × 10−3 cm/s)
non-significant difference
No single channel data
available
Pancreatic acinar
cells
Unknown [54,55]
2. Aquaporin Function
AQP channels facilitate the movement of water and small uncharged solutes across membranes
down a concentration gradient. As such, they are implicated in a myriad of diseases and AQP
modulators are thought to be promising therapeutic targets for new drug development [8,14]. In some
cases, compounds that modify the transcription and translation of AQPs may also be beneficial such as
modifying AQP7 expression as a treatment for obesity [14]. Most of the information currently known
about AQPs pertains to AQPs 1, 2, 3, and 4, which are the focus of this review. Table 1 shows the
currently-known structural and functional features of AQP family members. AQP4 appears to have
the highest known water permeability of the AQPs and its role as the major AQP within the central
nervous system (CNS) supports this, as tight control is required to ensure optimal conditions for CNS
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function. The lowest permeabilities are seen in AQP0 and AQP6. The main function of AQP0 as the
major intrinsic protein (MIP) in the eye lens (where it has a structural and adhesive function) means
that it does not require a high water permeability. AQP6 is an intracellular AQP, but its main function
is not yet known.
2.1. AQP1
AQP1 was first identified in red blood cells and is linked to pathologies such as cancer, the inability
to concentrate urine, and altered pain sensation [37,40,56]. Expression of AQP1 in some tumor types is
correlated with increased angiogenesis, invasion, metastasis, and growth [3,57]. Aggressive melanomas
were shown to have higher expression of AQP1. Silencing of the AQP1 gene in a mouse melanoma
xenograft model, reduced angiogenesis and metastasis [1]. In addition to this, it was found that
matrix metalloproteinase (MMP) 2 was downregulated upon AQP1 knockdown although it was not
determined which of AQP1 or MMP2 was important in mediating this effect [1]. AQP1 is also found in
the endothelial cells of the lungs and epithelial cells of bile ducts as well as the kidney tubules and in
the epithelia of the proximal convoluted tubule and the loop of Henle [10,47]. AQP1-deficient humans
are unable to concentrate their urine beyond 450 mOsm compared to the more normal 1000 mOsm
and above [8,58]. They are also prone to fluid accumulation in the lungs [47]. Modulating AQP1
may therefore lead to treatments that can aid conditions of excess fluid such as heart failure and
cirrhosis [3,10,14]. Another role of AQP1 is pain perception; its deletion can cause a reduction of pain
from inflammation or cold providing a possible basis for analgesia [3]. There is also evidence to show
AQP1 in the choroid plexus where cerebrospinal fluid is produced [47].
2.2. AQP2
AQP2 is found in the kidneys, specifically within the cells of the collecting duct. Its regulation
is one of the best-studied examples of hormone-mediated AQP translocation; following vasopressin
(anti-diuretic hormone) release, AQP2-containing vesicles translocate to the plasma membrane
facilitating water reabsorption [8,59]. Vasopressin binds to V2 receptors of the principal cells in
the renal collecting ducts, activating cAMP and protein kinase (PK) A, which phosphorylates Ser-256
and causes the exocytosis of AQP2-containing vesicles [25,60]. Central diabetes insipidus is the lack of
vasopressin and its key symptoms are polyuria with an inability to concentrate urine [61]. Nephrogenic
diabetes insipidus (NDI) is usually caused by a problem with the vasopressin receptor on collecting
duct cells and is often linked to the AQP2 gene expression [61]. There are also cases of inherited NDI
which can be caused by the same vasopressin receptor mutations but also mutations in the AQP2
gene; 19 such mutations have been identified [42,60]. Acquired diabetes insipidus is seen in cases
such as long term lithium therapy where AQP2 subcellular localization can become dysregulated
resulting in reduced surface localization and therefore loss of AQP2 function [47]. When vasopressin
is secreted inappropriately, high levels of water retention and hyponatremia occur [61]. This is also
seen in conditions such as congestive heart failure, where there is increased water retention due to
an upregulation of vasopressin, and consequently AQP2 expression and translocation to the plasma
membrane [60,62]. The exact mechanism by which AQP2 is recycled in the principal collecting duct
cells is not yet known, however clathrin-coated pits are thought to have a role in this process [63].
2.3. AQP3
AQP3 is an aquaglyceroporin that allows the transport of glycerol in addition to water [8]. It is
found in the epithelia of renal collecting ducts, urinary tract, digestive tract, and respiratory tract [47].
It is also found in the skin and aids skin hydration [13]. The overexpression of AQP3 is linked to skin
malignancies such as melanomas [64,65]. AQP3 knock-out (KO) mice have been shown to be resistant
to tumor formation in skin cancer models through reduced glycerol transport, resulting in lower ATP
formation and reduced cell proliferation [3,14,57,64]. AQP3 has also been shown to transport hydrogen
peroxide and this function aids NF-κB signaling. AQP3 KO mice had reduced H2O2 levels, impaired
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NF-κB activation and a reduced induction of psoriasis [66]. In addition to this, AQP3 has roles within
the normal function of bacterial phagocytosis by macrophages and the trafficking of T cells [3,67,68].
2.4. AQP4
AQP4 is the main water channel expressed in the CNS and is found at highest concentration in
astrocyte end-feet, which together with blood vessels form the blood–brain barrier (BBB) [13,69]. AQP4
expression is increased in cerebral edema and ischemia. This has been shown to be correlated with the
release of inflammatory cytokines [3,13,70,71]. AQP4 is also thought to aid the migration of astrocytes
when neuronal injury occurs and glial scars form [72]. AQP4 has been shown to have a link with
seizures where the regulation of cell volume by water flow can reduce susceptibility to seizures [73].
For the potassium channel, Kir 4.1, to be active, water flow through AQP4 is required [1,9,71,74,75].
During trauma or ischemia to the brain, there is a state of hypoxia which is then followed by a failure
in Na+, K+, and Cl− pumps in the plasma membrane, causing dysregulation of osmolality [56,76–78].
This results in an increased intracranial pressure (ICP) and cerebral edema due to water flow, primarily
into astrocytes during the cytotoxic phase of cerebral edema [70]. Limited therapeutic options are
currently available to control cerebral edema. They are restricted to the administration of hyperosmotic
solutions (such as mannitol, glycerol, and sodium chloride), hypothermia, or ultimately a surgical
intervention to remove part of the skull to alleviate the uncontrolled rise in ICP [70,79,80]. AQP4
inhibition may be beneficial in cytotoxic edema as AQP4 KO mice were protected from cytotoxic
edema. [3,13,14,56,70,81]. Vasogenic edema occurs due the movement of water and plasma proteins
across a leaky BBB [9,76]. In models of vasogenic edema, however, AQP4 KO resulted in worse
outcomes, due to an inability to remove excess water from brain tissue [3,9,56,70]. Any inhibition of
AQP4 function, therefore needs to be acute.
Neuromyelitis optica (NMO) is an autoimmune condition where the CNS is affected by
inflammation and demyelination [82]. It is symptomatically similar to multiple sclerosis (MS),
but there are some key differences including the fact that some treatments for MS can exacerbate
NMO [82]. Most patients with NMO have autoantibodies that target AQP4 in astrocytes and cause
complement- and cell-mediated cytotoxicity [83]. The usual treatment for NMO involves steroids and
other immunosuppressants such as azathioprine and mycophenolate [82].
2.5. AQPs 0, 5–12
AQP0, also known as MIP, was first identified within the lens. Its role is not only as a water
channel (it has a low permeability compared to other family members, Table 1) but also to maintain
the transparency and structure of the lens [35]. Mutations in the genes for AQP0 were found to result
in congenital cataracts [35,84].
AQP5 was first found within the submandibular glands and is now known to have a role within
many secretory glands including salivary, lacrimal, and sweat glands [85]. Binding of acetylcholine to
muscarinic M3 receptors is thought to induce the translocation of AQP5 vesicles to the cell surface
membrane and problems with this process have been shown to be linked to conditions such as Sjögren’s
syndrome [32,86,87].
AQP6 is an intracellular water channel found in vesicles and its water permeability is low [48],
as shown in Table 1. These vesicles also contain H+–ATPase and AQP6 has been found to become
more active at low pH suggesting that the role of AQP6 is in acid secretion [27,84].
AQP7, an aquaglyceroporin, is found in adipocytes and is thought to have a role in fat metabolism
aiding degradation of triglycerides in fasting states [8]. AQP7 KO mice are seen to have higher levels
of fat than wild type controls and this is thought to be a therapeutic target for obesity [13]. However,
in the case of an individual with a homozygous nonfunctional AQP7 mutation, body mass index,
cholesterol, and glucose levels were all normal, with only a reduced increase in glycerol levels during
exercise compared to controls [88].
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AQP8 has been identified in the brain, small intestine, testis, and the salivary glands [49].
Its function was disputed, but it is now known that AQP8 transports ammonia, as well as water, and
that the transport of ammonia may be its primary function, maintaining acid-base equilibrium [30].
AQP9, an aquaglyceroporin, is found in hepatocytes and its function is thought to be significant
during periods of exercise or prolonged fasting affecting glucose production [85]. It is found in
osteoclasts and is thought to have a role in osteoporosis [89]. It is also found in astrocytes and
leukocytes [43,49]. AQP9 and AQP7 are also known to mediate the uptake of arsenic compounds,
which are used in some cancer treatments [44].
Little is known about the remaining AQPs. AQP10, an aquaglyceroporin, is found in intestinal
epithelial cells and in adipocytes [43,47,90]. AQP11 is an intracellular aquaporin but its function
remains unclear [44]. AQP11 contains a cysteine residue instead of an alanine in its first NPA motif
and in the second motif, it has a leucine instead of an arginine [91]. It is found to be expressed in
the testis, brain, kidneys, and liver [43]. AQP11 KO mice have been found to die soon after birth
due to polycystic kidney disease [92]. This is thought to be due to AQP11 being required for correct
glycosylation of polycystin-1 and -2 [93]. AQP12 is expressed in pancreatic acinar cells and in AQP12
KO models, those that develop pancreatitis develop a much more severe pathology [54,55].
3. Aquaporin Assays
Water permeability can be assayed in various ways. Measuring volume change due to osmotic
gradients is one indirect approach. Epithelial assays are based on using epithelial tissues placed on
permeable supports and adding solutes to cause the fluid in a capillary tube to move. Transepithelial
flux is measured via this change and fluorescent dyes can be used to evaluate permeability [94,95].
Transepithelial permeability results from water flow that has occurred both cellularly and paracellularly,
whereas water flux through AQPs occurs only cellularly, which is a limitation of this as an approach to
deducing AQP function.
Osmotic swelling techniques are by far the most common methods used for assaying volume
changes and Xenopus oocytes are often used as they have a very low intrinsic water permeability [96].
Osmotic gradients are used and oocytes expressing AQPs change volume when these gradients
are altered [97]. While the use of Xenopus oocytes is very common, there is substantial variability
between oocyte preparations, meaning data may vary between laboratories even using the same
materials [94,98].
Microscopy techniques are also used to measure permeability via a fluorophore that is taken up
by cells. Esterases within the cell produce the active fluorophore and the rate of change of fluorophore
concentration can then be detected using a plate-reader or fluorescence microscope after an osmotic
gradient has been applied [99]. The limitation of this technique is that the fluorescence is relative to the
dimensions of the cell monolayer where thinner cells produce a larger relative change in fluorescence
than cell-lines that have a thicker monolayer. This can affect reproducibility in the same cell-line if
confluence is varied between assays. It is also dependent on the amount of fluorophore that is taken
up by the cells, which can sometimes be pumped out, producing variability in the data [100].
Stopped-flow spectroscopy involves the use of suspensions of cells, vesicles, or proteoliposomes
which are mixed with solutes to produce a change in volume. The difference in light-scattering after
this volume change can then be used to calculate the volume change [99]. Limitations of stopped-flow
spectroscopy techniques include the dead time and mixing ability of the instrument used [101,102].
Computational methods involve the use of high-resolution structures and molecular dynamics
simulations, which can provide new insights into AQP structure and function at atomic resolution.
However, high-quality structures are not always available and simulations can sometimes produce
data that are different from experimental data [94,103]. A summary of these techniques is shown in
Table 2.
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Table 2. Various assay methods used in the measurement of AQP function and the validation of AQP
inhibitors. Their benefits and limitations are shown.
Assay Type Assay Principle Benefits Limitations References
Epithelial Epithelial cells are placed on
supports, solutes are added
and transepithelial flux is
measured by the height of the
fluid in capillary tubes
Assists AQP identification
and characterization in
tissues
Individual membrane
permeability is calculated
Not very robust
Measures paracellular as
well as cellular water flow
[94,95]
Osmotic Swelling Osmotic gradients are used to
cause flux of solutes and water
in cells
endogenously-expressing or
transfected with AQP genes;
cell volume changes are
measured
Well-established technique
Oocytes have low intrinsic
water permeability
Other cells can be used
Inward and outward
gradients possible
Preparation techniques
vary causing
discrepancies in results
between laboratories
Not very reproducible
Variability between
oocytes
[94,96,98]
Microscopy Most often fluorescent dyes are
used that permeate the plasma
membrane and are cleaved by
esterases. As osmotic shock
occurs, the fluorescence is
altered, which is measured and
used to calculate cell volume
changes
Linear relationship
produced between
fluorophore and cell volume
changes
More accurate than
counterparts
Very sensitive
Robust
Thickness of cell-line
monolayer can produce
variability in results
Fluorophore may not
always stay within the
cell depending on
cell-line
[94,99,104]
Stopped-Flow
Spectroscopy
Suspensions of cells or vesicles
are mixed with various osmotic
solutions and flux of water
causes volume changes, which
result in altered light scattering.
The linear relationship between
optical properties and cell
volume allows permeability to
be calculated; alternatively
fluorophores can be used.
Fast kinetics measured
Can use cells, vesicles and
proteoliposomes
Linear relationship between
optical properties and
volume changes
Variability in dead time
and mixing ability can
cause problems with
reproducibility
[94,99,101]
Computational
Methods
High resolution atomic
structures of AQPs are used
and molecular dynamics
simulations allow in silico
measurement of water
permeability
Provides new insights into
AQP structure and function
High-quality structures
not always available
May disagree with
experimental data
[94,103]
4. Aquaporin Inhibitors
Most of the molecules that are currently under investigation as AQP inhibitors target AQPs 1, 2,
3, or 4. There are many patents, clinical trials, and studies on AQP up-regulators, modulators, and
inhibitors. For the purposes of this review, only AQP inhibitors are considered (Table 3).
Table 3. Currently-available AQP inhibitors, their structures, the AQPs they inhibit (species are
highlighted as h—human, m—mouse, and r—rat) and the conditions under which they were assayed.
Inhibitor Conditions AQPsInhibited Structure References
Tetraethyl- ammonium Xenopus oocytes100 µM hAQP1
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Copper sulfate Swan 71 cells100 µM hAQP3 [113]
Nickel chloride
Human bronchial
epithelium cells
1 mM
hAQP3
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Table 3. Cont.
Inhibitor Conditions AQPsInhibited Structure References
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rAQP1
rAQP4
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However, they have yet to b proven as definit ve AQP inhibitors. A n vel molecule n med TGN-020
has shown great promise very recently as an inhibitor in mouse models [81]. Micro RNA (miRNA)
and small interfering RNA (siRNA) have also been used to modulate AQPs [70]. Mercury chloride
binds to a pore-lining cysteine residue found on several (but not all) AQPs and blocks the channel [3].
Mercury and its compounds is known to be toxic due to their non-specificity which causes many
off-target effects [11]. Other heavy metal compounds (such as silver and gold compounds) have been
investigated as inhibitors, but the challenge is finding a molecule with a side-effect profile that is
tolerable. Currently-known inhibitors are discussed by type in the sections below.
4.1. Small Molecule Inhibitors
Tetraethylammonium (TEA) is a small molecule inhibitor that was first tested due to perceived
similarities between AQPs and ion channels. Using human AQP1 expressed in Xenopus oocytes,
a maximum single dose of 10 mM TEA caused a reduction in water permeability of 33% [105]. Another
study using 4 µM and 100 µM TEA showed an inhibition of 44% for Xenopus oocytes expressing AQP1,
with no differences at the two concentrations; TEA also inhibited AQP2 and AQP4, with maximal
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inhibition of 40% and 57%, respectively, at 100 µM TEA [123]. Further testing of TEA in Xenopus
oocytes or in native AQP1-expressing erythrocytes has failed to show inhibition [3,124]. TEA is thought
to act by binding to a tyrosine residue located on the extracellular end of transmembrane helix 5 [123].
Acetazolamide is a carbonic anhydrase inhibitor used in glaucoma to reduce aqueous humor
production and hence intraocular pressure [125]. It has been shown to be a reversible inhibitor of
AQP1 and AQP4 (Table 3). It has inhibitory effects on Xenopus oocytes expressing human AQP4
in a dose-dependent manner with maximal inhibition of 85% at the highest dose of 20 µM [126].
A reduction in the water permeability of rat AQP4 (assayed in proteoliposomes) to 46% was observed
at a maximum dose of 1.25 mM acetazolamide [127]. In HEK293 cells expressing rat AQP1, there was
a 39% reduction in water permeability with 100 µM acetazolamide compared to untreated rat AQP1
(using GFP fluorescence to measure swelling) [119]. However, acetazolamide appears to be unable to
inhibit endogenous AQPs in human cells [10,124].
Anti-epileptic drugs (AEDs) have also been suggested as possible AQP inhibitors [120]. Their
anti-epileptic action has been hypothesized take place through modulation of AQPs. Many AEDs
such as topiramate, zonisamide, and lamotrigine are known to have a similar inhibitory effect to
acetazolamide on carbonic anhydrase enzyme as well as an in silico predicted binding site on AQP4
that is similar to that hypothesized for acetazolamide [120]. AEDs had an inhibitory effect on AQP4 in
Xenopus oocytes [120], however, this could not be reproduced in rat thyroid epithelial cells [122]. AEDs
are thought to possibly have an inhibitory effect on AQP1, AQP4, and AQP5 [128]. However due
to their unconfirmed mechanisms of action and relatively non-specific action, there is no conclusive
evidence showing that AEDs are effective and safe AQP inhibitors [10,122].
TGN-020 was shown in mouse models to significantly reduce AQP4-mediated edema following
ischemia, but the molecule was administered before injury [81]. There was an approximately 10%
reduction in brain volume [81]. Therapeutic administration must necessarily occur after a stroke,
although a prophylactic treatment could be considered if the side effect profile of TGN-020 was
acceptable. TGN-020 has since been tested on the same middle cerebral artery occlusion (MCAO)
model and administered post-injury in mice. In a study using mouse models at a dose of 100 mg/kg,
TGN-020 was administered 15 minutes post-ischemic injury and treated animals had better motor
scores and less AQP4 expression around blood vessels when compared to untreated controls [129].
The half-maximal inhibitory concentration (IC50) of TGN-020 was 3µM in Xenopus oocytes expressing
human AQP4, but there is no evidence to show that TGN-020 is AQP4-specific [130].
Phloretin is a small molecule that acts as a non-specific aquaglyceroporin inhibitor. It has
also been shown to inhibit the urea transporter, UT-A1, found in the kidney [131]. It has been
speculated that the same mechanism underpinning urea inhibition is responsible for inhibition of the
aquaglyceroporins, AQP3 and AQP9 [107,132]. Then 100 µM of phloretin was used to inhibit AQP9
expressed in Xenopus oocytes, resulting in an 86% inhibition [107]. AQP3 glycerol permeability in
proteoliposomes was inhibited by 500 µM phloretin, producing 83% inhibition. Phloretin had no effect
on control proteoliposomes which had a Pgly of ~2.8 × 10−6 cm/s [108].
A recent study identified new inhibitors of the aquaglyceroporins, AQP3 and AQP7.
The compound DFP00173 was able to inhibit the glycerol permeability of human erythrocytes with an
IC50 of ~0.2 µM. Compound Z433927330 reduced glycerol permeability with an IC50 of ~0.6 µM. In a
Chinese hamster ovary cell-line, compound DFP00173 was able to inhibit mouse AQP3 with an IC50
of ~0.1 µM and was selective for AQP3 over AQP7 and AQP9. Compound Z433927330 was able to
inhibit mouse AQP7 in the same cell-line with an IC50 of ~0.2 µM and with selectivity for AQP7 over
AQP3 and AQP9; IC50s for this compound for mouse AQP3 and AQP9 were ~0.7 µM and ~1.1 µM,
respectively [121].
4.2. Heavy Metal Ion Inhibitors
Heavy metal compounds have been used in cytotoxic treatments for many years, with the use of
the platinum compound cisplatin being notable in cancer therapy. Many AQPs have been correlated
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with cancers, their presence influencing disease severity, increased local invasion, and the occurrence
of metastasis [57]. AQP1 overexpression has been identified in brain, breast, lung, renal, cervical,
ovarian, and colorectal cancers [133]. AQP3 overexpression has been found in skin, stomach, renal,
liver, colorectal, lung, and cervical cancers [134]. AQP3 is highly expressed in skin carcinoma cells.
The uptake of glycerol through AQP3 is thought to aid the growth of these cancer cells [57]. AQP4
overexpression is found in brain, lung, and thyroid cancers [135]. AQP5 overexpression has been
found in breast, cervical, colorectal, liver, lung, pancreatic, ovarian, and esophageal cancers [136].
AQP7 and AQP8 overexpression are found in thyroid and cervical cancer, respectively [133]. AQP9
overexpression has been found in brain, liver, and ovarian cancers [136].
Nickel chloride has been shown to inhibit AQP3 overexpressed in human bronchial epithelium
cells. Water permeability was reduced to approximately 60% in cells treated with 1 mM NiCl2
compared to non-transfected control cells [114]. Mutational studies showed that the extracellular
loop residues, Trp-128, Ser-152, and His-241, were all required for the observed inhibitory effect, but
that further studies are required to confirm similar effects in other AQP3-expressing tissues such
as the kidney [114]. Copper ions also inhibit AQP3 function and attempts to reduce the toxicity of
copper compounds have been addressed by using nanoparticles for delivery [57]. Copper sulfate has
been identified as an AQP3 inhibitor at 100 µM [113]. It is believed that copper ions act by binding
the same three residues on the extracellular loops as nickel ions [137]. This inhibition mechanism is
different from that of mercury ions, which bind to Cys-40 in AQP3 [137,138]. Copper compounds
have been shown to specifically inhibit AQP3 and not AQP4, AQP5, or AQP1 [137], while other AQPs
remain to be tested. Gold-based compounds have also been used as AQP3 inhibitors and have been
shown to be effective. AQP3 is found in erythrocytes, alongside AQP1, however its role is mostly for
glycerol rather than both water and glycerol permeability [110]. Erythrocytes showed a 90% decrease
in glycerol permeability following treatment with 50 µM AuPhen. The binding of this gold compound
is thought to be via Cys-40 and inhibition can be almost completely reversed by the addition of the
reducing agent, 2-mercaptoethanol [110]. AuPhen and other Au(III) compounds such as Auterpy
were also compared with copper and platinum compounds as AQP3 inhibitors [111,139]. Due to their
effective inhibition of glycerol transport in AQP3, they were tested on AQP7, another aquaglyceroporin.
Initial results have demonstrated that 15 µM AuPhen inhibited water and glycerol transport through
AQP7 [111]: there was a reduction in water permeability (63%) as well as glycerol permeability (79%).
Adipocytes overexpressing hAQP7 were used and permeability was measured using loading with
5 µM of calcein-AM and hyperosmotic shock. In silico docking studies suggest that Auphen binds
AQP7 through an interaction with Met-47 [140]. Silver has also been used as a possible AQP inhibitor
and is found to produce a rapid and irreversible inhibition of AQP1 in erythrocytes [112]. It has
been shown to be a much more potent inhibitor of AQP1 in erythrocytes than mercury, [112]. Silver
nitrate and silver sulfadiazine were tested as inhibitors to prevent shrinking of human erythrocytes in
hyperosmotic solutions. A dose-response curve was used to calculate an IC50 of 3.9 µm and 1.24 µm
and a 60% and 75% inhibition for silver nitrate and silver sulfadiazine, respectively. Gold and silver
are thought to bind to sulfhydryl groups on cysteine residues of AQPs, but the complete mechanisms
are not yet understood [110–112].
5. Antibody Treatments
An anti-AQP4 monoclonal antibody was developed as a potential treatment for NMO.
“Aquaporumab” competitively binds to AQP4 in astrocytes and displaces AQP4-IgG, reducing NMO
lesions in mouse models [82,83]. This is yet to be tested in humans, although in vivo studies have been
promising [141].
6. Patents and Clinical Trials
A search of the European Patent Office archive in February 2019 returned 484 AQP-related
patents or patent applications. These documents protect various techniques and methods such as
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AQP upregulation and modulation, detection methods, mRNA expression, as well as siRNA silencing
techniques. Approximately 40 of these patents are for inhibitors of AQPs or NMO treatments.
US patent 2008/0194513 A1 identifies the proliferation of blood vessels within the eyes as a factor
in sight loss in several ocular conditions. Interfering RNAs were therefore used to silence AQP4
mRNA expression in order to reduce ocular neovascularization. Administration of siRNA at 1–10
nM provided over 70% inhibition of AQP4 expression in Madin-Darby canine kidney (MDCK) cells
transfected with human AQP4 compared to controls [142]. A similar patent was filed by the same
inventors using similar techniques for the inhibition of AQP1 expression for ocular conditions [143].
US patent 7,659,312 B2 identifies various AQP4 inhibitors to be used in cerebral edema and other
water-related disorders. Twenty-one compounds are described that are similar in structure to the
loop diuretics, furosemide, and bumetanide. A total of 15 compounds had inhibitory effects on AQP4
when tested in Xenopus oocytes transfected with AQP4-M23. 20 µM inhibitor compounds were used
and experiments were completed twice. Aryl sulphonamide-like compounds and bi-aryl compounds
were identified as inhibitors. Docking energies were also analyzed using AQP4 monomers built from
electron diffraction structures; compounds with higher inhibition often had better docking energies.
Phenylbenzamide-based compounds are patented inhibitors of AQP2 and AQP4 for the treatment
of AQP-related conditions such as edema, ischemic stroke, epilepsy, and meningitis. Phenylbenzamides
such as niclosamide, a compound usually used for treatment of helminth infections, is known to have
an inhibitory effect on NF-kB and IKK-β. The compound IMD-0354 was used to inhibit IKK-β in
myocardial ischemia models [144]. Compound 3 has a similar structure to IMD-0354 but the two
trifluromethyl groups are replaced by chloride. Compound 3 is claimed to be an inhibitor of AQP2,
AQP4-M1, and AQP4-M23 with over 60% inhibition. It was at very poor inhibitor of AQP1 and
AQP5. Compound 1 (IMD-0354) inhibited cerebral edema formation in a murine water toxicity model.
Treatment with 0.76 mg/kg produced an 11.2% reduction, while 7.6 mg/kg showed a 15.9% reduction
in edema. Following MCAO in mice, there was a 29.4% increase in survival 24 h post-injury [118].
A subsequent patent described prodrug salts of these compounds [145].
Ghrelin is a 28 amino acid peptide that is secreted by gastric mucosa cells and is a hormone
that regulates hunger. It is known to also have other anti-inflammatory properties thought to be
protective in neuronal injury [146]. Traumatic brain injury (TBI) causes acute, elevated ICP and brain
damage. Repeated mild brain injuries (mBI), such as concussions, can cause long-term injury to the
brain and increased risk of neurodegeneration with aging. Treatments for TBI and mBI are very limited.
Administration of ghrelin reduced the levels of reactive oxygen species in neurons and volume loss in
mice post-injury [147]. The administration of ghrelin at doses 1.5–1000 times native levels provided
therapeutic effects lasting from 30 minutes up to 24 h. Ghrelin was also able to reduce oxidative bursts
post mBI [148]. Ghrelin has been shown to reduce levels of brain water after acute hypoxia in rats, as
well as the permeability of blood vessels. It is thought to do this through reduction in TNF-α levels
together with other anti-inflammatory effects on IL1, IL6, and NF-κB [149]. In another study, levels
of AQP4, serum S100B and vascular permeability were quantified to show disruption of the BBB
post-TBI in mice. Treatment with ghrelin was able to reduce these levels and help prevent BBB damage
post-TBI [150].
A possible NMO treatment centers on a peptide corresponding to AQP4 loop C. T cells reactive
to this peptide from AQP4 -/- mice produced a pathological response reminiscent of NMO when
injected into AQP4 +/+ mice. T cells are found in NMO lesions and are thought to be required for
the production of anti-AQP4 IgG. It was noted that immunosuppression therapy would be required
before treatment takes place [151].
US patent 2015/0224108 A1 presents techniques to create prodrugs and derivatives of the loop
diuretics, bumetanide and furosemide, as AQP inhibitors and to aid their administration to the site of
action [152].
The use of phloretin as an AQP9 inhibitor was shown to reduce osteoclast levels. This inhibition
would aid treatment in conditions such as osteoporosis, where excessive bone resorption takes place.
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AQP9 expression is higher in osteoclasts than other cells; 50 µM phloretin inhibited AQP9 expression,
causing a reduction in size and number of osteoclasts but not their precursors [153].
A search of the US National Library of Medicines Clinical Trials archive in February 2019 returned
61 clinical trials involving AQP-based treatments. Several of these trials examine urinary AQP2 levels
and the conditions under which they are altered. Several trials also examine NMO, MS, and the
therapeutic use of AQP4-IgGs. A search of the University Hospital Medical Information Network
(UMIN) - Clinical Trials Registry in February 2019 returned two current clinical trials taking place using
anti-AQP4 IgGs. There are currently no clinical trials taking place in the UK using AQP inhibitors or
anti-AQP4 IgGs according to the UK Clinical Trials Gateway.
7. Discussion
Finding inhibitors for AQP water channels has been considerably more challenging than first
thought. The identification of molecules that inhibit water transport through specific AQP isoforms is
not a simple proposition for drug discovery on account of the high level of structural conservation
within the AQP family (Table 1). The small diameter of all AQP-pores together with the chemical
properties of the pore-lining amino acid side-chains mean that hydrophilic compounds are unlikely to
enter and block them.
No definitive, small molecule AQP inhibitors have been identified to date that could be
used therapeutically. Heavy metal compounds are certainly effective AQP inhibitors, but their
non-specificity and toxicity substantially limit their therapeutic potential. Using liposomes to
administer heavy metal compounds would reduce off-target effects, but more research is required.
The most promising AQP inhibitor with clinical potential to date is TGN-020, which has not yet shown
any side effects in vivo, but is yet to be tested in human clinical trials. Notably, antibodies used for
NMO treatment have no effect on water permeability. There is a clear need for AQP modulators,
particularly in conditions such as TBI where, in the early stages, AQP4 inhibition is required to manage
cytotoxic edema but, thereafter, upregulation of AQP4 would aid clearance of vasogenic edema.
The lack of reliable in vitro phenotypic assays suitable for screening and validating the
pharmacological regulation of AQP function (Table 2), means that pharmaceutical companies have
been unable to meet the challenge of developing small molecules that block the AQP pore. For example,
molecules discovered using Xenopus oocytes consistently fail to show efficacy in mammalian cells and
vice versa. Screening programs for AQP inhibitors should therefore include multiple assays that allow
more robust and reproducible readouts.
8. Conclusions
AQPs are expressed ubiquitously and have implications in myriad human diseases. The progress
of identifying AQP inhibitors has been slow and as research continues, AQPs are increasingly
implicated in more diseases, highlighting the clear and urgent need for AQP modulators. More
research is needed to find effective AQP inhibitors. Current screening processes are extremely
variable. Approaches to standardize assays would be beneficial in identifying promising molecules for
future study.
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Abbreviations
AQP aquaporin
NPA Asn-Pro-Ala
Å Ångstrom
CNS central nervous system
MIP major intrinsic protein
RNA ribonucleic acid
cRNA complementary ribonucleic acid
MMP matrix metalloproteinase
cAMP cyclic adenosine monophosphate
PKA protein kinase A
NDI nephrogenic diabetes insipidus
KO knock-out
BBB blood–brain barrier
ICP intracranial pressure
NMO neuromyelitis optica
MS multiple sclerosis
AEDs anti-epileptic drugs
miRNA micro ribonucleic acid
siRNA small interfering ribonucleic acid
TEA tetraethylammonium
µM micromolar
HEK293 human embryonic kidney 293
MCAO middle cerebral artery occlusion
IC50 half maximal inhibitory concentration
NiCl2 nickel chloride
mM millimolar
GFP green fluorescent protein
hAQP human aquaporin
calcein-AM calcein acetoxymethyl
AgNO3 silver nitrate
AgSul silver sulfadiazine
IgG immunoglobulin G
mRNA messenger ribonucleic acid
qPCR quantitative polymerase chain reaction
ELISA enzyme-linked immunosorbent assay
nM nanomolar
NF-κB nuclear factor kappa-light-chain-enhancer of activate B cells
IKK-β inhibitor of nuclear factor kappa-B
24h 24 hours
TBI traumatic brain injury
mBI mild brain injury
TNF-α tumor necrosis factor alpha
IL1 interleukin 1
IL6 interleukin 6
UMIN University Hospital Medical Information Network
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